Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2007

Open Access 01-10-2007 | Editorial

The UK NCRI MAGIC Trial of Perioperative Chemotherapy in Resectable Gastric Cancer: Implications for Clinical Practice

Authors: Yu Jo Chua, MBBS, David Cunningham, MD, FRCP

Published in: Annals of Surgical Oncology | Issue 10/2007

Login to get access

Excerpt

The 503-patient United Kingdom National Cancer Research Institute (NCRI) Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial is the first randomized trial to demonstrate a conclusive survival benefit from the use of perioperative chemotherapy for patients with resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus, compared with surgery alone.1 In the intention-to-treat (ITT) analysis, patients who received perioperative chemotherapy with the ECF regimen (epirubicin, cisplatin, and continuous infusion 5-fluorouracil, 5FU) had a 5-year survival of 36%, compared with 23% in patients treated with surgery alone (hazard ratio for death, 0.75; 95% confidence interval, 0.60–0.93; P = 0.009). Progression-free survival was also improved by perioperative chemotherapy (hazard ratio for progression, 0.66; 95% confidence interval, 0.53–0.81; P < .001). These results support the use of this treatment strategy as an option for patients with resectable gastric cancer as an alternative to postoperative chemoradiotherapy, which has been shown in a previous randomized trial (the US Intergroup 0116 trial, INT 0116) to also be of benefit in these patients, and are expected to influence the standard treatment of this disease particularly in the UK and Europe.2 …
Literature
1.
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11–20PubMedCrossRef
2.
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725–30PubMedCrossRef
3.
Waters JS, Norman A, Cunningham D, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 1999; 80:269–72PubMedCrossRef
4.
Webb A, Cunningham D, Scarffe JH, et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15:261–7PubMed
5.
Ross P, Nicolson M, Cunningham D, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 2002; 20:1996–2004PubMedCrossRef
6.
Cunningham D, Rao S, Starling N, et al. Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial. J Clin Oncol 2006; 24:abstr 4017
7.
8.
Fielding J, Peake D. Treatment of gastric cancer. N Engl J Med 2006; 355:1386–7; author reply 1387–8PubMedCrossRef
9.
Singh J, Williamson SK, Malani AK. Treatment of gastric cancer. N Engl J Med 2006; 355:1386; author reply 1387–8PubMedCrossRef
10.
Boot H, Jansen EP, Cats A. Treatment of gastric cancer. N Engl J Med 2006; 355:1387; author reply 1387–8PubMed
11.
Jani K. Treatment of gastric cancer. N Engl J Med 2006; 355:1387; author reply 1387–8PubMed
12.
Briasoulis E, Fatouros M, Roukos DH, Kappas AM. Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 2007; (in press)
13.
Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the “different disease” hypothesis. Cancer 2000; 88:921–32PubMedCrossRef
14.
Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79:1522–30PubMedCrossRef
15.
Macdonald JS, Smalley S, Benedetti J, et al. Postoperative combined radiation and chemotherapy improves disease-free survival (DFS) and overall survival (OS) in resected adenocarcinoma of the stomach and gastroesophageal junction: Update of the results of Intergroup Study INT-0116 (SWOG 9008). Program and Proceedings of the 2004 Gastrointestinal Cancers Symposium, San Francisco, CA: abstr 6
16.
Cunningham D, Allum WH, Stenning SP. Treatment of gastric cancer. N Engl J Med 2006; 355:1387–8CrossRef
17.
Hartgrink HH, van de Velde CJ, Putter H, et al. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol 2004; 30:643–9PubMedCrossRef
18.
Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266:93–8PubMedCrossRef
19.
Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24:5201–6PubMedCrossRef
20.
Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91:173–80PubMedCrossRef
21.
Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005; 23:4853–5PubMedCrossRef
Metadata
Title
The UK NCRI MAGIC Trial of Perioperative Chemotherapy in Resectable Gastric Cancer: Implications for Clinical Practice
Authors
Yu Jo Chua, MBBS
David Cunningham, MD, FRCP
Publication date
01-10-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 10/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9423-7

Other articles of this Issue 10/2007

Annals of Surgical Oncology 10/2007 Go to the issue

Breast Oncology

Treatment Trends and Factors Associated with Survival in T1aN0 and T1bN0 Breast Cancer Patients

Gastrointestinal Oncology

Prognostic Significance of VEGF Expression in Correlation With COX-2, Microvessel Density, and Clinicopathological Characteristics in Human Gastric Carcinoma

Breast Oncology

Mechanisms of HER2-Induced Endothelial Cell Retraction

Breast Oncology

Frozen Section Analysis for Intraoperative Margin Assessment During Breast-Conserving Surgery Results in Low Rates of Re-excision and Local Recurrence

Breast Oncology

Fusion of Magnetic Resonance and Scintimammography Images for Breast Cancer Evaluation: A Pilot Study

Gastrointestinal Oncology

Outcomes of Salvage Surgery for Squamous Cell Carcinoma of the Anal Canal